Shanghai Shyndec Pharmaceutical Co Ltd Cash Flow Conversion Efficiency
Shanghai Shyndec Pharmaceutical Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Shanghai Shyndec Pharmaceutical Co Ltd (600420) has a cash flow conversion efficiency ratio of 0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥486.04 Million ≈ $71.12 Million USD) by net assets (CN¥15.70 Billion ≈ $2.30 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Shanghai Shyndec Pharmaceutical Co Ltd (2004–2025)
Cash flow conversion efficiency of Shanghai Shyndec Pharmaceutical Co Ltd from 2004 to 2025. This chart illustrates how Shanghai Shyndec Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 600420 live share price for real-time trading data and today's change.
Shanghai Shyndec Pharmaceutical Co Ltd Cash Flow Conversion Ratio Explained
Shanghai Shyndec Pharmaceutical Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Shanghai Shyndec Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Shyndec Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Also see Shanghai Shyndec Pharmaceutical Co Ltd market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Opple Lighting Co Ltd
SHG:603515
|
1.061x |
|
Dime Community Bancshares, Inc.
NASDAQ:DCOM
|
0.032x |
|
Changjiang Publishing & Media Co Ltd
SHG:600757
|
0.037x |
|
Neinor Homes SLU
MC:HOME
|
0.068x |
|
FRIEDR.VORW.GRP. ADR/025
F:VH20
|
0.147x |
|
Suzhou Crystal Clear Chemical Co Ltd
SHE:300655
|
0.062x |
|
Sichuan Tuopai Shede Wine Co Ltd
SHG:600702
|
-0.039x |
|
Hamburger Hafen und Logistik Aktiengesellschaft
F:HHFA
|
0.069x |
Annual Cash Flow Conversion Efficiency for Shanghai Shyndec Pharmaceutical Co Ltd (2004–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai Shyndec Pharmaceutical Co Ltd from 2004 to 2025. Review 600420 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥34.93 Billion ≈ $5.11 Billion |
CN¥1.70 Billion ≈ $248.48 Million |
0.049x | -66.98% |
| 2024-12-31 | CN¥15.32 Billion ≈ $2.24 Billion |
CN¥2.26 Billion ≈ $330.12 Million |
0.147x | +22.71% |
| 2023-12-31 | CN¥14.34 Billion ≈ $2.10 Billion |
CN¥1.72 Billion ≈ $251.74 Million |
0.120x | -48.94% |
| 2022-12-31 | CN¥12.15 Billion ≈ $1.78 Billion |
CN¥2.86 Billion ≈ $417.87 Million |
0.235x | +45.07% |
| 2021-12-31 | CN¥10.37 Billion ≈ $1.52 Billion |
CN¥1.68 Billion ≈ $245.79 Million |
0.162x | +1.94% |
| 2020-12-31 | CN¥9.82 Billion ≈ $1.44 Billion |
CN¥1.56 Billion ≈ $228.30 Million |
0.159x | +15.13% |
| 2019-12-31 | CN¥9.20 Billion ≈ $1.35 Billion |
CN¥1.27 Billion ≈ $185.86 Million |
0.138x | -30.19% |
| 2018-12-31 | CN¥8.44 Billion ≈ $1.24 Billion |
CN¥1.67 Billion ≈ $244.25 Million |
0.198x | -34.68% |
| 2017-12-31 | CN¥7.65 Billion ≈ $1.12 Billion |
CN¥2.31 Billion ≈ $338.69 Million |
0.303x | +150.41% |
| 2016-12-31 | CN¥6.94 Billion ≈ $1.02 Billion |
CN¥838.58 Million ≈ $122.71 Million |
0.121x | -14.06% |
| 2015-12-31 | CN¥1.61 Billion ≈ $235.83 Million |
CN¥226.65 Million ≈ $33.17 Million |
0.141x | -24.27% |
| 2014-12-31 | CN¥1.39 Billion ≈ $203.72 Million |
CN¥258.51 Million ≈ $37.83 Million |
0.186x | +18.60% |
| 2013-12-31 | CN¥1.33 Billion ≈ $193.92 Million |
CN¥207.50 Million ≈ $30.36 Million |
0.157x | -3.62% |
| 2012-12-31 | CN¥1.19 Billion ≈ $174.21 Million |
CN¥193.41 Million ≈ $28.30 Million |
0.162x | +13.10% |
| 2011-12-31 | CN¥947.63 Million ≈ $138.67 Million |
CN¥136.12 Million ≈ $19.92 Million |
0.144x | +4.53% |
| 2010-12-31 | CN¥837.59 Million ≈ $122.57 Million |
CN¥115.11 Million ≈ $16.84 Million |
0.137x | +0.63% |
| 2009-12-31 | CN¥713.46 Million ≈ $104.40 Million |
CN¥97.43 Million ≈ $14.26 Million |
0.137x | +48.57% |
| 2008-12-31 | CN¥631.47 Million ≈ $92.40 Million |
CN¥58.04 Million ≈ $8.49 Million |
0.092x | -33.63% |
| 2007-12-31 | CN¥594.29 Million ≈ $86.96 Million |
CN¥82.31 Million ≈ $12.04 Million |
0.138x | -3.74% |
| 2006-12-31 | CN¥511.49 Million ≈ $74.85 Million |
CN¥73.60 Million ≈ $10.77 Million |
0.144x | +19.00% |
| 2005-12-31 | CN¥478.84 Million ≈ $70.07 Million |
CN¥57.90 Million ≈ $8.47 Million |
0.121x | +213.99% |
| 2004-12-31 | CN¥441.88 Million ≈ $64.66 Million |
CN¥17.02 Million ≈ $2.49 Million |
0.039x | -- |
About Shanghai Shyndec Pharmaceutical Co Ltd
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company provides nifedipine controlled release tablets, penicillin industrial potassium salt, touboke yuekui granules/capsules, sodium cefuroxime for injection, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, and… Read more